Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostate Cancer Patients 1

Interventions

Docetaxel 33Radiosurgery 23Radiotherapy 21Sunitinib 20pembrolizumab 18Gemcitabine 16Cisplatin 16Androgen Antagonists 15Nivolumab 14enzalutamide 13Goserelin 13Prednisone 12Leuprolide 12Blood Specimen Collection 12Abiraterone Acetate 12bicalutamide 11aldesleukin 11Surveys and Questionnaires 11Cyclophosphamide 11Gonadotropin-Releasing Hormone 10Bevacizumab 10Multiparametric Magnetic Resonance Imaging 9Carboplatin 9acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 8Triptorelin Pamoate 8Radiotherapy, Intensity-Modulated 8Filgrastim 8Epirubicin 8Chemotherapy, Adjuvant 8Brachytherapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × repaglinide × Genitourinary × Clear all
NCT04664725 2020-12-11

Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
18 enrolled
Genitourinary

Prostate Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡